EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Wip1 Inhibition Enhances the Therapeutic Efficacy of Palbociclib in Luminal A Breast Cancer by Modulating Cell Cycle Progression and Apoptosis

Gökhan Çolak, Nazllcan Kaygusuz, Nezih Meydan, Esin Oktay, Mehtap Kılıc Eren

Folia Biologica · 2026 · 72 (2) · 59-67

DOI: 10.14712/fb2026.0006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Folia Biologica, online erschienen am 17.04.2026. Verfasst von Gökhan Çolak und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Department of Medical Oncology, Aydin Adnan Menderes University, Aydin, Türkiye. Hauptthemen laut MEDLINE: Protein Phosphatase 2C, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Breast Neoplasms. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Adnan Menderes Üniversitesi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors such as palbociclib have improved the treatment of hormone receptor-positive, luminal A breast cancer; however, therapeutic resistance remains a major challenge. Wild-type p53-induced phosphatase 1 (Wip1) is a negative regulator of the p53 pathway and is often over-expressed in luminal breast cancers. This study aimed to determine whether Wip1 inhibition enhances the anti-proliferative and pro-apoptotic effects of the CDK4/6 inhibitor palbociclib in luminal A breast cancer cells and to elucidate the underlying cell cycle-related mechanisms. MCF-7 cells were treated with palbociclib and Wip1 inhibitor GSK2830371, alone or in combination. Cell viability was assessed using the WST-1 assay, cell cycle distribution was analysed by flow cytometry, and apoptosis was evaluated using Annexin V/7-aminoactinomycin D staining. Expression of cell cycle regulators (CDK2, CDK4, CDK6, cyclin D1/D3, Rb, phospho-Rb) and p53-related proteins (p53, phospho-p53 Ser15, p21, p27) was determined by Western blot analysis. The combined treatment produced a concentration-dependent reduction in cell viability and a marked increase in both early and late apoptotic populations compared with monotherapies. While palbociclib alone induced G1 arrest, co-treatment with GSK2830371 shifted cells toward G2 accumulation. This was accompanied by enhanced phosphorylation of p53, up-regulation of p21 and p27, and dephosphorylation of Rb, indicating dual checkpoint engagement. These findings demonstrate that Wip1 inhibition augments palbociclib-mediated cell cycle arrest and apoptosis through modulation of the p53-Rb axis. The dual blockade of Wip1 and CDK4/6 may represent a promising therapeutic strategy for p53-proficient luminal A breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Phosphatase 2CCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Breast NeoplasmsMCF-7 CellsHumansProtein Kinase InhibitorsApoptosisCell CycleAminopyridinesDipeptidesPiperazinesPyridines

Stichwörter der Autor:innen

CDK4/6 inhibitorsWip1 phosphataseapoptosiscell cycle arrestluminal A breast cancer

Substanzen

PPM1D protein, humanProtein Phosphatase 2CpalbociclibProtein Kinase InhibitorsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6GSK2830371AminopyridinesDipeptidesPiperazines

Autor:innen und Institutionen

  • Faculty of Medicine, Department of Medical Oncology, Aydin Adnan Menderes University, Aydin, Türkiye.
  • Faculty of Medicine, Department of Medical Biology, Aydin Adnan Menderes University, Aydin, Türkiye.
  • Izmir Biomedicine and Genome Center, Dokuz Eylul University, Izmir, Türkiye.
  • Department of Medical Oncology, Medicana International Hospital University, Istanbul, Türkiye.
  • ADU-BILTEM, Aydin Adnan Menderes University, Aydin, Türkiye. mkilic@adu.edu.tr.
  • Faculty of Medicine, Department of Medical Biology, Aydin Adnan Menderes University, Aydin, Türkiye. mkilic@adu.edu.tr.

Förderung

  • Adnan Menderes Üniversitesi

Zitieren

APA

Çolak, G., Kaygusuz, N., Meydan, N., Oktay, E., & Kılıc Eren, M. (2026). Wip1 Inhibition Enhances the Therapeutic Efficacy of Palbociclib in Luminal A Breast Cancer by Modulating Cell Cycle Progression and Apoptosis. Folia Biologica, 72(2), 59-67. https://doi.org/10.14712/fb2026.0006

Vancouver

Çolak G, Kaygusuz N, Meydan N, Oktay E, Kılıc Eren M. Wip1 Inhibition Enhances the Therapeutic Efficacy of Palbociclib in Luminal A Breast Cancer by Modulating Cell Cycle Progression and Apoptosis. Folia Biologica. 2026;72(2):59-67. doi:10.14712/fb2026.0006

BibTeX
@article{olak2026,
  author = {Çolak, Gökhan and Kaygusuz, Nazllcan and Meydan, Nezih and Oktay, Esin and Kılıc Eren, Mehtap},
  title = {Wip1 Inhibition Enhances the Therapeutic Efficacy of Palbociclib in Luminal A Breast Cancer by Modulating Cell Cycle Progression and Apoptosis},
  journal = {Folia Biologica},
  year = {2026},
  volume = {72},
  number = {2},
  pages = {59--67},
  doi = {10.14712/fb2026.0006}
}
Kostenlos starten →